Tenderwize
Retour à la recherche

Non-exclusive Ibuprofen Discount Agreement

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 28, 2027 · 184 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ibuprofen (ATC-Code nach WHO: M01AE01)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

Unknown demand and no guaranteed minimum volumes; actual revenue is highly uncertain.

Agreement may be terminated early if exclusive discount agreements are signed by AOK PLUS.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of Ibuprofen film tablets (ATC M01AE01) under a non-exclusive discount agreement
  • Pharmaceutical companies must be eligible under § 130a Abs. 8 SGB V and § 4 Abs. 18 AMG
Afficher le résumé complet

Non-exclusive drug discount agreement (Rabattvereinbarung) for Ibuprofen (ATC M01AE01) film tablets under an Open House model with AOK PLUS. The agreement is open to all qualified pharmaceutical companies during the participation period. No guaranteed minimum quantities, no exclusive supply, and individual negotiations are not conducted. The agreement ends 28 February 2027, with possible early termination if exclusive agreements are concluded. This publication is for transparency and not a formal public procurement under EU directives.

Risques

Unknown demand and no guaranteed minimum volumes; actual revenue is highly uncertain.

Agreement may be terminated early if exclusive discount agreements are signed by AOK PLUS.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined in § 4 Abs. 18 AMG with respect to the offered drugs

Eligibility

  • Submit declaration of no exclusion grounds (§§ 123, 124 GWB)

Administrative

  • Submit declaration regarding EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576)

Critères d'attribution

Lot 1

No award criteria specified; this is a non-competitive Open House model, not a traditional tender.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Ibuprofen Discount Agreement

Conclusion of non-exclusive discount agreements for prescription drugs with active ingredient Ibuprofen (ATC M01AE01) in film tablet form. Open House model: any interested pharmaceutical company can join if they meet the conditions. No minimum purchase quantities, unknown demand dependent on prescription behavior.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2025 - Feb 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; this is a non-competitive Open House model, not a traditional tender.

Date limite

Expired May 05, 2025

Détails de la procédure

Date de publication
13 Feb 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
102408-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30